Welcome to Quest PharmaTech Inc.

Quest PharmaTech is a publicly traded (QPT:TSXV), Canadian based pharmaceutical company developing products to improve the quality of life. The Company through its subsidiary, OncoQuest is developing antibody based immunotherapeutic products for cancer. In addition, the Company owns the Photodynamic Therapy technology for oncology and dermatology applications, licensed to BioCeltran Co., Ltd. (Bioceltran), a Korea based company. Quest has an ownership interest in Bioceltran which is focused on SP Technology™ for transdermal delivery of drugs and photosensitizers for pharmaceutical and cosmetic purposes. Quest, through its subsidiary, Madenco Biosciences, will be focusing on the development of pharmaceutical products for dermatology and would healing applications. Quest is also developing an antibody licensed from the University of Nebraska, Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications (OncoCare Therapeutics).

Link to Quest PharmaTech Inc. Fact Sheet


Please note that Quest PharmaTech (“Quest”) has become aware of a SCAM going on in the name of our Company and the names of current/past Quest personnel. The Scam promises a lucrative job with our company in Canada to residents of India in return for fees.

Please note – it is not our practice to hire any non-Canadians for employment.

The Scammers have been using a similar (but not identical) website name of www.questspharmatech.com (note there is an extra ”s” between “quest” and “pharmatech”) or the e-mail address of questpharmatech.inc@chemist.com.

Press releases 2020

June 4, 2020
Quest Provides Corporate Update

May 29, 2020
Quest Provides Additional Information on OncoQuest Transaction and Announces Delay in Annual Filings

April 22, 2020
OncoQuest Signs a Definitive Agreement to Sell Drug Portfolio to Dual Industrial for U.S. $300 Million and Commitment to Fund the Oregovomab Phase 3 Clinical Trial in Frontline Ovarian Cancer

March 24, 2020
OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company’s Lead Investigational Drug in Frontline Ovarian Cancer

March 13, 2020
OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.

Press releases 2019

September 25, 2019
OncoQuest Receives “Notice of Allowance” for Patent Protection of the Administration Schedule of Oregovomab and Chemotherapy for Stage III-IV Ovarian Cancer Patients

January 29, 2019
Quest PharmaTech Announces Results from AGM

January 25, 2019
OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer

Press releases 2018

December 19, 2018
Quest PharmaTech Adopts Amendment to By-laws Requiring Advance Notice of Nomination of Directors

December 3, 2018
Quest PharmaTech Announces Adoption of Shareholder Rights Plan

November 28, 2018
Quest PharmaTech Signs License Agreement with OncoCare Therapeutics to Develop and Commercialize Targeted Cancer Therapy Technology in the U.S.

July 20, 2018
Madenco Biosciences Announces Strategic Decision to Drop Consumer Health Products and Focus on Pharmaceutical Product Development

June 1, 2018
Abstract Describing Use of Oregovomab in Pancreatic Cancer to be Published in JCO as Part of ASCO 2018 Meeting

May 14, 2018
Dr. Eliel Bayever Joins OncoQuest as Chief Medical Officer

February 12, 2018
OncoQuest to Present at BIO CEO & Investor Conference

February 6, 2018
OncoQuest Completes US $6 Million Private Placement

January 3, 2018
Madenco Biosciences Announces Licensing Agreement for Patented EGF Wound Healing Technology

Press releases 2017

November 14, 2017
OncoQuest Announces Presentation of Pre-Clinical Data from its IgE Based Immunotherapy Platform Technology at the 32nd Annual Society for Immunotherapy of Cancer (SITC)

November 7, 2017
OncoQuest Announces Presentation of Translational Immunology Data from Phase 2 Clinical Study Examining Oregovomab in Combination with Chemotherapy in Front Line Ovarian Cancer at the InternationalMeeting of European Society of Gynaecological Oncology (ESGO) 2017

November 6, 2017
Quest PharmaTech Announces Results from its November 2017 AGM

October 26, 2017
OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer Setting

August 28, 2017
Quest PharmaTech Receives $1,666,667 of Funding Proceeds Through Exercise of Warrants

July 19, 2017
Quest PharmaTech Appoints Mr. Mark Lievonen, former President of Sanofi Pasteur Limited, to the Board of Directors

May 24, 2017
OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 18, 2017
Madenco Biosciences Creates New Line of Cosmeceuticals to Complement Bellus Skin™ Serum for Anti-Aging

May 9, 2017
OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer

May 4, 2017
Quest PharmaTech Expands Its Consumer Health Product Pipeline with Clinically Validated Natural Allergy Relief

February 15, 2017
Quest PharmaTech Announces Results from its 2017 AGM

Press releases 2016

December 7, 2016
OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

November 29, 2016
OncoQuest Announces Positive Interim Results from Its Phase 2b Clinical Study

November 14, 2016
Bellus Skin Rejuvenation Serum: Quest PharmaTech Launches
Scientifically Proven, Clinically Validated Premium Skin Care Cosmetics in Canada

November 2, 2016
OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer

October 28, 2016
Quest PharmaTech Inc. Announces Change of Auditor

October 20, 2016
Anti-MUC1 MAb AR20.5 Induces Specific Cell Mediated Immune Response to MUC1 Antigen in Pre-Clinical Pancreatic Cancer Model

September 16, 2016
Quest PharmaTech Inc. Amends Warrant Terms

September 6, 2016
Quest PharmaTech Inc. Retains Haft Group for Financial Services

August 5, 2016
Quest PharmaTech Announces Filling of Restated Audited Financial Statements for the Year Ended January 31, 2016 and for the Quarter Ended April 30, 2016

Mar 22, 2016
Quest PharmaTech’s Subsidiary, OncoQuest, Signs Agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. to Fund Immunotherapy for Treatment of Cancer in China

Press releases 2015

Dec 10, 2015
Quest PharmaTech Receives U.S. $2 Million for its ImmunoPhotodynamic Therapy Assets

Dec 1, 2015
Quest PharmaTech Announces Results from its 2015 AGM